![John Meewella](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Meewella
Amministratore Delegato presso Akinion Pharmaceuticals AB
Posizioni attive di John Meewella
Società | Posizione | Inizio | Fine |
---|---|---|---|
Akinion Pharmaceuticals AB
![]() Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Amministratore Delegato | - | - |
Storia della carriera di John Meewella
Statistiche
Distribuzione geografica
Svezia | 2 |
Posizioni
Chief Executive Officer | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Akinion Pharmaceuticals AB
![]() Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
- Borsa valori
- Insiders
- John Meewella
- Esperienza